Dianthus Therapeutics Inc DE

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

DNTH$88.81-1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three Months EndedMarch 31,
	2025	2024
Revenues:
License revenue - related party	$—	$874
License revenue	1,163	—
Total revenues	1,163	874
Operating expenses:
Research and development	27,003	13,078
General and administrative	7,337	5,640
Total operating expenses	34,340	18,718
Loss from operations	(33,177)	(17,844)
Other income/(expense):
Interest and investment income	3,791	4,222
Loss on investment in related party	(5)	—
Loss on currency exchange, net	(22)	(12)
Other expense	(98)	(114)
Total other income	3,666	4,096
Net loss	$(29,511)	$(13,748)
Net loss per share attributable to common stockholders, basic and diluted	$(0.82)	$(0.54)
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted	35,790,700	25,665,475
Comprehensive loss:
Net loss	$(29,511)	$(13,748)
Other comprehensive income/(loss):
Unrealized gain/(loss) on marketable securities	164	(74)
Total other comprehensive income/(loss)	164	(74)
Total comprehensive loss	$(29,347)	$(13,822)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.